Nexhibe Nuhii

Nexhibe Nuhii

Auto-generated profile, based on publicly available information

Nexhibe Nuhii


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
Gazmend TEMAJGazmend TEMAJ
Gazmend TEMAJ
RHRifat Hadžiselimović
Rifat Hadžiselimović
HNHilada Nefic
Hilada Nefic
NNNexhibe Nuhii
Nexhibe Nuhii
Introduction: The process of protein synthesis is a vital process for all kingdoms of life. The ribosome is a ribonu­cleoprotein complex that reads the genetic code, from messenger RNA (mRNA) to produce proteins and to tightly regulate and ensure cells growth. The fact that numerous diseases are caused by defect during the ribosome biogenesis is important to understand this pathway. Materials and methods: We have analyzed the literature for ribosome biogenesis and its links with different diseases which have been found. Results and discussion: We have discussed the key aspect of human ribosome biogenesis and its links to diseases. We have also proposed the potential of applying this knowledge to the development of a ribosomal stress-based cancer therapy. Conclusion: Major challenges in the future will be to determine factors which play a pivotal role during ribosome bio­genesis. Therefore, more anti-cancer drugs and gene therapy for genetic diseases will be developed against ribosomal biogenesis in the coming years. Graphical

Verified
Open access
EBEmir Behluli
Emir Behluli
NNNexhibe Nuhii
Nexhibe Nuhii
Thomas LiehrThomas Liehr
Thomas Liehr
Gazmend TEMAJGazmend TEMAJ
Gazmend TEMAJ
Children with Down syndrome (DS) are at markedly increased risk for acute lymphoblastic leukaemia (ALL). DS is caused by trisomy of chromosome 21 affecting approximately 1 in 732 newborns in the USA. ALL is the most common cancer in children and constitutes approximately 25% of cancer diagnoses among children under the age of 15. Different protocols for treatment and management of paediatric ALL are available; however, DS children with ALL (DS-ALL) have increased risk of therapy-related toxicity compared to those without DS. Herein, we summarize the available literature on inherited predisposition for ALL, and possibilities for molecular therapy and treatment for DS-ALL patients.

30 October 2026 in BioTechnologia
Verified
Journal Article
Closed access
PDF file
YGYllka Gashi
Yllka Gashi
ATAnjeza Temaj
Anjeza Temaj
NNNexhibe Nuhii
Nexhibe Nuhii
Merita XhetaniMerita Xhetani
Merita Xhetani
HNHilada Nefic
Hilada Nefic
Gazmend TEMAJGazmend TEMAJ
Gazmend TEMAJ
The ribosome is a ribonucleoprotein complex that translates messenger RNA (mRNA) sequences into polypeptide chains. Ribosome biogenesis is a highly complex process with a pivotal role in many cellular processes, including proliferation, differentiation, apoptosis, development, and malignant transformation. Nonsense mutation introduces premature termination codons (PTCs), resulting in early termination of translation and synthesis of truncated proteins. Readthrough therapy aims to enhance suppression and consequently restore the production of full-length proteins. This approach has yielded considerable success over the years and has shown promising outcomes in many disorders associated with nonsense mutations; however, applying this approach to treat skin diseases remains challenging. This review summarizes current investigations on nonsense suppression strategies pertaining to epidermolysis bullosa. We focus on aminoglycosides that induce PTC readthrough, the small molecule PTC124 (ataluren), and inhibitors of nonsense-mediated mRNA decay. We also examine some emerging compounds that target the translational machinery and may become relevant for future nonsense mutation suppression therapy.